NCT07066540View on ClinicalTrials.gov

Trial of the Efficacy and Safety of Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Viral Enteric Infection
Interventions
DRUG

Reamberin® solution for infusion, 1.5 %

Reamberin® in daily dose 10 mL/kg

Trial Locations (8)

Unknown

RECRUITING

South Ural State Medical University, Chelyabinsk

RECRUITING

Khimki Clinical Hospital, Khimki

RECRUITING

Kuban State Medical University, Krasnodar

RECRUITING

Infectious Diseases Clinical Hospital No. 1, Moscow

RECRUITING

Z.A. Bashlyaeva Children's City Clinical Hospital, Moscow

RECRUITING

Penza Regional Clinical Center for Specialized Types of Medical Care, Penza

RECRUITING

Children's Scientific and Clinical Center for Infectious Diseases of the Federal Medical and Biological Agency, Saint Petersburg

RECRUITING

Samarkand State Medical University, Samarkand

All Listed Sponsors
lead

POLYSAN Scientific & Technological Pharmaceutical Company

INDUSTRY